Biome Australia Secures Ethics Approval for First Human Trial of Proprietary Probiotic BMB18

Biome Australia Ltd ( (AU:BIO) ) has issued an update.

Biome Australia has received ethics approval from La Trobe University’s Human Research Ethics Committee to commence its first human clinical trial of its proprietary probiotic strain Lactobacillus plantarum BMB18 in February 2026. The 12‑month, randomised, double-blind, placebo-controlled study will enroll 240 adults to assess BMB18’s efficacy on digestive symptoms, sleep, mood and quality of life at two active dosage levels versus placebo, with the work to be delivered within the company’s existing R&D budget. As a wholly owned and DSMZ-registered strain, BMB18 represents protectable intellectual property, and successful clinical validation is expected to underpin new product development and licensing opportunities across Biome’s Activated Probiotics and Activated Therapeutics ranges, bolster its competitive advantage, and support growth in its core gut health category while advancing its Vision 27 strategic plan.

The most recent analyst rating on (AU:BIO) stock is a Hold with a A$0.46 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.

More about Biome Australia Ltd

Biome Australia Limited is a microbiome health company listed on the ASX that develops probiotic-based products under its Activated Probiotics and Activated Therapeutics ranges, with a major focus on gut disorders and targeted gut health. The company is building a portfolio of proprietary, clinically validated strains and leverages research partnerships, including with La Trobe University, to strengthen its intellectual property and market position in evidence-based gut health solutions.

Average Trading Volume: 265,003

Technical Sentiment Signal: Sell

Current Market Cap: A$100.2M

Find detailed analytics on BIO stock on TipRanks’ Stock Analysis page.